Nuvaira Develops First Targeted Therapy for COPD Phenotype
MINNEAPOLIS, Minnesota, July 1, 2026 Nuvaira, Inc. has announced the first patient treated in the pivotal AIRFLOW-4 clinical trial...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
MINNEAPOLIS, Minnesota, July 1, 2026 Nuvaira, Inc. has announced the first patient treated in the pivotal AIRFLOW-4 clinical trial...
TURIN, Italy | June 19, 2026 Kither Biotech has announced the successful completion of its first-in-human Phase 1 clinical...
